Results about: iproteos

Iproteos, IRB Barcelona’s spin-off specialised in drugs to treat diseases of the central nervous system, is taken over by Accure Therapeutics

Iproteos, one of the 5 spin-offs launched by IRB Barcelona, focuses on the development of third-generation drugs for diseases such as schizophrenia, epilepsy, and atherosclerosis.

Its proprietary technology allows faster research processes to identify new drugs and produce novel molecules.

The new company Accure Therapeutics starts up with €7.6 M of investment, which will allow the development of its product portfolio and the takeover of Iproteos and Bionure.

IRB Barcelona presents its technology and capacities at the 2017 BIO International Convention

IRB Barcelona, along with another 30 Catalan companies and organisations, is participating in the four-day convention in San Diego.

The BIO International Convention (BIO) is the top partnering fair for the biomedical sector.

The Institute’s spin-offs Iproteos and Nostrum Biodiscovery are also visiting the fair.

IRB Barcelona’s Innovation Department is ready for partnering at BIO-Europe Spring 2017

The 11th international partnering conference comes to Barcelona from 20 to 22 March.

19 young researchers at IRB Barcelona will also be attending the three-day conference.

BIO-Europe Spring is the premier springtime partnering conference for the biotechnology industry.

A study reveals the effectiveness of a cognitive enhancer for schizophrenia treatment

Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

Iproteos closes a round of funding valued at 1.5 million Euros

The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.

The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia  (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.  

Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.